1214341-16-8

Basic information

• Product Name: 2-Fluoro-3-nitrobenzoyl chloride
• Synonyms: Benzoyl chloride, 2-fluoro-3-nitro-
• CAS NO: 1214341-16-8
• Molecular Formula: C₇H₃ClFNO₃
• Molecular Weight: 203.56
• Mol File: 1214341-16-8.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Fluoro-3-nitrobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-3-nitrobenzoyl chloride(1214341-16-8)
• EPA Substance Registry System: 2-Fluoro-3-nitrobenzoyl chloride(1214341-16-8)

Safety Data

• Hazardous Substances Data: 1214341-16-8(Hazardous Substances Data)

Upstream product

• 96516-29-9 2-fluoro-3-nitrobenzaldehyde 
• 317-46-4 2-fluoro-3-nitro-benzoic acid 

Downstream Products

• 1254318-20-1 N-[2-ethyl-4-(1,2,2,3,3,3-hexafluoro-1-trifluoromethylpropyl)-6-methylphenyl]-2-fluoro-3-nitrobenzamide 
• 1312942-00-9 (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)(2-fluoro-3-nitrophenyl)methanone 
• 1254567-33-3 (3-amino-2-fluorophenyl)(5-bromo-1H-pyrrolo[2,3-b]pyridin- 3-yl)methanone 
• 1312942-01-0 N-[3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-2-fluoro-benzenesulfonamide 
• 1312940-70-7 2-fluoro-N-{2-fluoro-3-[5-(2-methoxy-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-benzenesulfonamide 
• 1301189-83-2 1,1-dimethylethyl (3S)-3-[({2-[(methylamino)carbonyl]-6-nitrophenyl}amino)methyl]-1-pyrrolidinecarboxylate 
• 1301189-84-3 2-({[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}amino)-N-methyl-3-nitrobenzamide 
• 1301189-86-5 3-amino-2-({[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}amino)-N-methylbenzamide 

Relevant articles and documents

Surprisingly High Selectivity and High Affinity in Mercury Recognition by H-Bonded Cavity-Containing Aromatic Foldarands

In the absence of macrocyclic ring constraints, few synthetic systems, possessing a mostly solvent-independent well-folded conformation that is predisposed for highly selective and high affinity recognition of metal ions, have been demonstrated. We report here such a unique class of conformationally robust modularly tunable folding molecules termed foldarands that can recognize Hg2+ ions surprisingly well over 22 other metal ions. Despite the lack of sulfur atoms and having only oxygen-donor atoms in its structure, the best foldarand molecule, i.e., tetramer 4, exhibits a selectivity factor of at least 19 in differentiating the most tightly bound Hg2+ ion from all other metal ions, and a binding capacity that is ≥18 times that of thio-crown ethers. These two noteworthy binding characters make possible low level removal of Hg2+ ions. With a [4]:[Hg2+] molar ratio of 5:1 and a single biphasic solvent extraction, the concentration of Hg2+ ions could be reduced drastically by 98% (from 200 to 4 ppb) in pure water. 4 could also effect a highly efficient reduction in mercury content by 98% (from 500 to 10 ppb) in artificial groundwater via multiple successive extractions with an overall consumption of 4 being 9:1 in terms of [4]:[Hg2+] molar ratio.

Amide compound as well as preparation method and application thereof

The invention provides an amide compound as well as a preparation method and application thereof. The amide compound has a structure as shown in a formula I in the specification. The amide compound disclosed by the invention can have high insecticidal act

Novel pyrimidine sulfonamide derivatives and a mite controlling composition comprising thereof

The present invention relates to a novel amide derivative and a composition for controlling an acaricide comprising the same. By introducing a heterocyclic substituent into the amide derivative, a composition for controlling an acaricide activity can be p

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

Hereditary angioedema (HAE) is a rare and potentially life-threatening disease that affects an estimated 1 in 50000 individuals worldwide. Until recently, prophylactic HAE treatment options were limited to injectables, a burdensome administration route that has driven the need for an oral treatment. A substantial body of evidence has shown that potent and selective plasma kallikrein inhibitors that block the generation of bradykinin represent a promising approach for the treatment of HAE. Berotralstat (BCX7353, discovered by BioCryst Pharmaceuticals using a structure-guided drug design strategy) is a synthetic plasma kallikrein inhibitor that is potent and highly selective over other structurally related serine proteases. This once-daily, small-molecule drug is the first orally bioavailable prophylactic treatment for HAE attacks, having successfully completed a Phase III clinical trial (meeting its primary end point) and recently receiving the U.S. Food and Drug Administration's approval for the prophylactic treatment of HAE attacks in patients 12 years and older.